{"id":1968,"date":"2017-03-15T12:17:55","date_gmt":"2017-03-15T12:17:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1968"},"modified":"2021-10-12T11:15:20","modified_gmt":"2021-10-12T05:45:20","slug":"the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer","title":{"rendered":"New biomarkers for screening in Pancreatic Cancer"},"content":{"rendered":"<p>Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel, consisting of plasma tissue factor pathway inhibitor (TFPI) and tenascin-C (TNC-FN-III-C), as measured in plasma samples using an ELISA improves the prognostic value of CA\u00a019-9. This biomarker panel enabled accurate discrimination between patients with, and those without early stage PDAC, and was also effective in discriminating between patients with diabetes or pancreatitis and those with PDAC. These findings improve upon the prognostic effectiveness of CA\u00a019-9, the previous gold-standard biomarker.<\/p>\n<p>To read more, click <a href=\"http:\/\/www.nature.com\/nrclinonc\/journal\/vaop\/ncurrent\/full\/nrclinonc.2017.35.html\">Pancreatic Cancer biomarkers<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel, consisting of plasma tissue factor pathway inhibitor (TFPI) and tenascin-C (TNC-FN-III-C), as measured in plasma samples using an ELISA improves the prognostic value of CA\u00a019-9. This biomarker panel enabled accurate discrimination between patients with, and those [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1969,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[806,805,427,449,17486,739],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-1968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-adenocarcinoma","tag-biomarkers","tag-oncology","tag-pancreatic-cancer","tag-pdac","tag-snippet","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New biomarkers for Pancreatic Cancer | DelveInsight<\/title>\n<meta name=\"description\" content=\"Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New biomarkers for Pancreatic Cancer | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-15T12:17:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-12T05:45:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021832\/pan.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"399\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New biomarkers for Pancreatic Cancer | DelveInsight","description":"Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer","og_locale":"en_US","og_type":"article","og_title":"New biomarkers for Pancreatic Cancer | DelveInsight","og_description":"Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-03-15T12:17:55+00:00","article_modified_time":"2021-10-12T05:45:20+00:00","og_image":[{"width":600,"height":399,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021832\/pan.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer","name":"New biomarkers for Pancreatic Cancer | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021832\/pan.jpg","datePublished":"2017-03-15T12:17:55+00:00","dateModified":"2021-10-12T05:45:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-biomarkers-improve-standard-screening-in-pancreatic-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021832\/pan.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021832\/pan.jpg","width":600,"height":399},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021832\/pan-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">adenocarcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Biomarkers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pancreatic Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">PDAC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippet<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">adenocarcinoma<\/span>","<span class=\"advgb-post-tax-term\">Biomarkers<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Pancreatic Cancer<\/span>","<span class=\"advgb-post-tax-term\">PDAC<\/span>","<span class=\"advgb-post-tax-term\">Snippet<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 15, 2017","modified":"Updated on Oct 12, 2021"},"absolute_dates_time":{"created":"Posted on Mar 15, 2017 12:17 pm","modified":"Updated on Oct 12, 2021 11:15 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1968"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1968\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1969"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1968"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1968"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}